Pentixapharm Gets FDA Go-Ahead for Phase III Trial of Radiopharmaceutical Diagnostic for Primary Aldosteronism

WÜRZBURG, Germany, June 25, 2024 — Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, announced it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) following a recent Type C meeting. This meeting was to discuss the possibility of proceeding directly into a pivotal phase III registration study for its radiopharmaceutical diagnostic Ga68-PentixaFor in Primary Aldosteronism (PA). PA is an adrenal gland disorder, also known as Conn’s syndrome, and is the most frequent cause of secondary hypertension (high blood pressure).

While the FDA minutes from the Type C meeting do not represent a formal approval, they indicate that the clinical data gathered by independent academic groups could serve as confirmatory evidence. This could potentially exempt Pentixapharm from the requirement to conduct a second controlled clinical investigation. The minutes also acknowledge that Ga68-PentixaFor addresses an unmet medical need for a serious condition. This fulfills two essential criteria for fast track and breakthrough designation, which Pentixapharm can request with its Investigational New Drug (IND) submission to initiate the phase III trial.

Ga68-PentixaFor is a novel tracer used in positron emission tomography (PET) imaging of aldosterone-hypersecreting adenomas in patients with PA. The prevalence of this disease has significantly increased over time, exceeding 20% in some resistant hypertension populations1. The disorder is characterized by either a unilateral aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). The current gold standard for differentiating these conditions is adrenal venous sampling (AVS), a complex and invasive procedure. While most patients with unilateral PA who undergo adrenalectomy after successful AVS experience complete biochemical normalization2, there is a risk of misdiagnosing a bilateral case. In such cases, patients would not benefit from the removal of the gland.

Dr. Dirk Pleimes, Chief Scientific & Medical Officer at Pentixapharm AG, commented: “The FDA feedback represents a major milestone for our Company in the development of our lead diagnostic. We aim to evaluate Ga68-PentixaFor as a first-in-class, non-invasive and accurate alternative to adrenal venous sampling. This has the potential to transform diagnostic subtyping in Primary Aldosteronism and improve patient outcomes. This discussion with US regulatory authorities provided important feedback, enabling us to proceed to a US-centric registrational phase III trial to support global authorization applications.”

About Pentixapharm AG

Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. It is wholly owned by the Eckert & Ziegler Group, one of the world’s largest providers of isotope technology for medical, scientific and industrial use. Pentixapharm is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular and endocrine diseases.

[1] Yozamp N, Vaidya A. The Prevalence of Primary Aldosteronism and Evolving Approaches for Treatment. Curr Opin Endocr Metab Res. 2019 Oct;8:30-39. doi: 10.1016/j.coemr.2019.07.001. Epub 2019 Jul 9. PMID: 32832727; PMCID: PMC7442120.

[2] Zhou, Y., Zhang, M., Ke, S., & Liu, L. (2017). Hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis. BMC endocrine disorders, 17(1), 1-9.

For more information, please contact:

Eckert & Ziegler SE
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10,
13125 Berlin, Germany
Tel.: +49 30 / 94 10 84-138

Pentixapharm AG
Phillip Eckert, Investor Relations
Tel. +49 30 94 10 84 227

Media Contact:
MC Services AG
Anne Hennecke
Tel. +49 211 529252 22